AI/ML/NLP in Clinical Trials and Drug Development: Challenges, Best Practices and the Road Ahead

Artificial intelligence is moving from experimentation to execution in clinical research. The opportunity is to use AI, machine learning and NLP to improve how clinical development teams make decisions.

Clinical trials have always been data-intensive. What has changed is the scale, speed and diversity of the data being generated.

Today, clinical development teams work across electronic data capture systems, laboratory data, imaging, biomarkers, patient-reported outcomes, real-world data and an expanding range of digital sources. The challenge is extracting meaningful signals from it quickly enough to influence decisions.

This is where AI in clinical trials, machine learning in drug development and AI-enabled clinical data analytics are beginning to change the operating model.

AI can identify patterns that may otherwise be difficult to detect. Machine learning can support prediction. Natural language processing can make unstructured information more accessible. Advanced analytics can bring disparate sources of evidence together.

But there is an important qualification.

Clinical development is not a prediction exercise alone. A model can identify an association. A statistician must determine how much confidence to place in it. A clinical expert must understand what it means in context. And ultimately, the evidence must be sufficiently robust, transparent and traceable for its intended purpose.

From retrospective analysis to forward-looking decision-making

For decades, biostatistics has been central to clinical development. Statisticians help sponsors design studies, define endpoints, analyze data, quantify uncertainty and interpret results.

Much of this work, however, has traditionally focused on answering questions about data that have already been generated.

AI and machine learning create the possibility of asking different questions much earlier:

What is likely to happen?
Where could a trial encounter problems?
Which patients are more likely to respond or discontinue?
What does historical data tell us about the feasibility of a proposed study?
Where should clinical teams focus their attention?

This does not diminish the role of statistical science. It expands it.

Machine learning can help uncover patterns across large and complex datasets, while biostatistical methods provide the framework for understanding uncertainty, controlling error and distinguishing meaningful evidence from patterns that may simply arise from the data.

That distinction will become increasingly important as AI moves deeper into the drug development lifecycle.

How is AI being used in clinical trials?

The most valuable applications of AI are likely to be those that address specific problems across the clinical trial lifecycle rather than those that simply demonstrate what an algorithm can do.

Designing better trials

Before the first patient is enrolled, sponsors make decisions about study populations, eligibility criteria, endpoints, sites and recruitment assumptions. Historical clinical trial data and other relevant datasets can provide useful context for these decisions.

Machine learning can help identify patterns in patient populations, recruitment performance and study characteristics. Used appropriately, this can support clinical trial feasibility, enrollment forecasting and study design optimization.

The important point is that AI should inform the decision rather than make it in isolation. Clinical and statistical expertise remains necessary to determine whether a pattern is meaningful and whether it should influence the study design.

Improving recruitment and retention

Recruitment delays can have a disproportionate impact on clinical development timelines.

AI and predictive analytics can help clinical teams understand where recruitment may slow down, identify characteristics associated with enrollment patterns and explore factors associated with patient dropout.

The value comes from moving the conversation earlier, from why are we behind? to where might we encounter difficulty and what can we do about it?

Understanding treatment response

As precision medicine advances, sponsors are increasingly interested in understanding why patients respond differently to the same treatment.

Machine learning can analyze multiple variables simultaneously, from baseline characteristics and biomarkers to treatment exposure and clinical outcomes, to identify patterns associated with treatment response.

A model may indicate that two variables are associated. It does not, by itself, establish why that relationship exists. This is precisely where biostatistics, clinical expertise and rigorous validation remain essential.

What does AI-augmented biostatistics mean for clinical development?

AI-augmented biostatistics is an evolving way of combining established statistical expertise with AI and advanced analytics.

The distinction is important.

AI can accelerate pattern recognition, automate repetitive processes and support prediction. Biostatistics provides the scientific framework to determine whether those outputs are reliable and meaningful.

In practice, that could mean using AI-assisted tools to support data review while statisticians focus on the implications of what the data is showing. It could mean automated quality checks that flag unusual observations for expert review. It could mean richer visualization of clinical data using our OneClinical platform which is the integration of SAS, R and Power BI, enabling study teams to identify trends more quickly.

Navitas Life Sciences’ approach can support deliverables across the clinical development lifecycle, from statistical analysis plans and statistical programming to interim analyses, clinical study reports and regulatory submissions. The technology becomes an enabler rather than the centre of the story.

What role will NLP play in clinical research?

Protocols, clinical narratives, medical records, safety information and other documents contain large amounts of valuable information in unstructured form. Natural language processing can help organizations extract and organize this information at scale.

This makes NLP in clinical research particularly interesting.

NLP can support activities such as document analysis, information extraction, classification and terminology processing. When combined with clinical expertise and appropriate validation, these capabilities can make previously difficult-to-analyze information more accessible.

Turning AI into measurable value

For sponsors, the question ultimately comes down to value.

Can AI reduce the time required to review clinical data?
Can it help identify potential issues earlier?
Can it improve the consistency of statistical workflows?
Can it make complex clinical data easier to interpret?
Can it support faster generation of regulatory-grade evidence?
And can all of this happen while maintaining the scientific standards expected in clinical development?

These are more useful questions than simply asking whether an organization is “using AI.”

Navitas Life Sciences’ approach is to integrate AI-assisted data review, advanced analytics, automated quality checks and data visualization with established expertise in clinical data management, biostatistics and statistical programming.

The technology can take on repetitive, data-intensive activities. Experts remain responsible for interpretation, validation and scientific decision-making. That balance is where AI can create sustainable value.

Meet Navitas Life Sciences at PHUSE Chennai Single Day: Silver Sponsor

This conversation comes to life at the PHUSE Chennai Single Day Event on 19 September 2026, where industry professionals will explore:

AI/ML/NLP in Clinical Trials & Drug Development – Challenges, Best Practices and the Road Ahead

 

If you are exploring how AI can move beyond experimentation and deliver practical value across clinical development, connect with the Navitas Life Sciences team at PHUSE Chennai Single Day.

Learn more about our services and solutions by reaching out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..